Find a Clinical Trial

Showing 141 - 150 of 171 Trials

A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Radiotherapy with or without Temozolomide and in Recurrent Glioblastoma as Single Agent

Principal Investigator:

Mikhail Doubrovin, MD

Contact Number:

212-342-5162

NCT Number:

NCT05109728

Population:

Adult

Phase:

I

The purpose of the study is to evaluate the safety of Lutathera alone in patients with recurrent glioblastoma and the combination of Lutathera with radiotherapy with temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GB) and to establish the appropriate dose of this combination. Lutathera is a radioligand therapy, which is a targeted treatment that selectively delivers radiation to the tumor, with limited damage to surrounding tissues. Lutathera uses a radioactive particle (lutetium-177) attached to a targeting compound that binds to a specific protein on the tumor cells (...
A Phase 1, First-in-Human, multicenter, open-label trial ofDS9051b in participants with advanced or metastaticadrenocortical carcinoma (ACC) and metastatic castrationresistantprostate cancer (mCRPC)

Principal Investigator:

Alexander Z. Wei, MD

Contact Number:

212-342-5162

NCT Number:

NCT07189403

Population:

Adult

Phase:

I

he purpose of this trial is to learn more about an investigational drug called DS9051b. DS9051b is an investigational drug that is not Food and Drug Administration (FDA) approved for your disease. This is a first in human study. It is being studied to see if it is safe, and if your disease improves while taking it. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must be able to swallow the study drug - Must not have known gastrointestinal disease or procedure that may interfere with absorption of the study drug
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 asMonotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT07277413

Phase:

I

The purpose of this study is to determine the ideal dose of the study drugs, IDE892 by itself and IDE892 in combination with IDE397, and to find out what effect, good and/or bad, these study drugs may have on your cancer. This will be first human study for IDE892. Both IDE892 and IDE397 has not been approved by the United States (US) Food and Drug Administration (FDA). Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must be willing and able to provide blood/tumor tissue samples for biomarker testing - Must be able to swallow and retain the study drug
A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in KRAS

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT05379985

Population:

Pediatrics/Adult

Phase:

I

The purpose of this study is to test an experimental drug called RMC-6236 (the study drug) for solid tumor cancer with a KRAS mutation. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of your cancer cells. RMC-6236 is an experimental drug, which means that it is not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC-6236 will be tested in humans. The safety of...
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT04794699

Population:

Adult

Phase:

I

IDE397 is an investigational drug, which has not been approved by health authorities for the treatment of people with your medical condition. It is currently not “on the market” (available for you to receive a prescription for and/or to buy) in any country. In this study, different dose levels of IDE397 will be tested. About 40 patients are expected to participate at approximately 6-8 study centers within the US. At a minimum, 2 patients will be enrolled in each dose level. There will be about 10 dose levels tested (starting at 5 mg). Every time a dose level is found to be safe, a...
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

Principal Investigator:

Ran Reshef, MD, MSc

Contact Number:

212-342-5162

NCT Number:

NCT04989803

Population:

Adult

Phase:

I

You have been invited to participate in this study because you have relapsed and/or refractory B-cell lymphoma and standard therapies available to treat your disease have limited effectiveness. The purpose of this study is to find out if the experimental products, KITE-363 and KITE-753, are safe and effective in treating your relapsed and/or refractory B-cell lymphoma. Participants will receive either KITE-363 or KITE-753 one time through into the vein (IV) infusion. The experimental treatment would involve removing some of your immune cells, genetically engineering those cells to identify...
CHRONIC CONVECTION ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT MALIGNANT GLIOMA

Principal Investigator:

Jeffrey N Bruce, MD

Contact Number:

212-342-5162

Population:

Adult

Phase:

I

The purpose of this study is to determine the safety of directly injecting a chemotherapy drug called Topotecan and a contrast agent called Gadolinium into malignant brain tumors. Currently there is no effective treatment for recurrent malignant brain tumors, which means the brain tumor has returned after the original tumor has been treated. Most systemic chemotherapy drugs have toxic side effects, which make them difficult to use for brain tumors. However, we are doing this study to find out if using an experimental method of directly infusing the drug into the tumor, allows research...
CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against Tcell non-Hodgkin lymphoma (NHL): a first-in-human phase I clinical trial

Principal Investigator:

Ran Reshef, MD, MSc

Contact Number:

212-342-5162

NCT Number:

NCT06420089

Population:

Adult

Phase:

I

The purpose of this study is to test whether Senza5 CART5 is safe to give to participants with T-cell non-Hodgkin lymphoma (NHL). The study will also test how Senza5 CART5 cells affect your cancer and how long they survive in your body. It will take some of your white blood cells, called T cells, and modify them with the hopes that they target the cancer cells or cells that help the cancer to grow. The change involves adding or altering the genes in your T cells, which are part of your immune system. The modified cell product given in this study is called Senza5 CART5. Senza5 CART5 is...
FORAGER-1: A Phase 1, Open-Label, Multicenter Studyof LOXO-435 (LY3866288) in Locally Advanced orMetastatic Solid Tumors Including Urothelial Cancer withFGFR3 Alterations

Principal Investigator:

Alexander Z. Wei, MD

Contact Number:

212-342-5162

NCT Number:

NCT05614739

Population:

Adult

Phase:

I

You are being asked to participate in this study because you have cancer that is late in stage or spread to other parts of the body that includes the lining of urinary tract. The purpose of this study is to see whether LY3866288 is safe, the possible side effects, how well your disease responds to treatment study drug and which does level of study drug should be tested and is the most optimal for patients in future studies along with Pembrolizumab and Enfortumab Vedotin. LY3866288 is an investigational study drug which mean it is not approved by the United States Food and Drug Administration...
First-in-Human, Phase 1/1b, Open-label, Multicenter Study ofBifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapyand in Combination Therapy in Patients with EGFR-DrivenAdvanced Solid Tumors

Principal Investigator:

Catherine Shu, MD

Contact Number:

212-342-5162

NCT Number:

NCT04429542

Population:

Adult

Phase:

I

This is a first-in-human clinical research study. This study is sponsored by a biopharmaceutical company named Bicara Therapeutics. The main purpose of this study is to investigate the study drug BCA101 alone and BCA101 in combination with pembrolizumab for its safety, the way the body absorbs, distributes, and gets rid of this study drug, how the study drug acts on the body, and whether it works on your cancer in patients with advanced cancer like you. Subjects will receive either BCA101 alone or BCA101 in combination with pembrolizumab until disease worsens, the subject stops benefitting...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages